Peptides and compounds that bind to elongation initiation factor 4E
By designing the peptides with specific amino acid sequences to bind to eIF4E, the problem of cap-dependent translation disorder caused by difficult inhibition of eIF4E activity in the prior art is solved, and effective inhibition of cancer is achieved.
Patent Information
- Application Number
- CN202080025505.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-29
- Filing Date
- 2020-03-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-03-30
AI Technical Summary
The prior art is difficult to effectively regulate and inhibit the activity of the extension initiation factor 4E (eIF4E), resulting in the problem of cap-dependent translation dysregulation in cancer.
A peptide containing a specific amino acid sequence was developed, such as CEX1GX2X3X4X5C, where X1 is threonine, methionine or leucine, X2 is a hydrophobic or aromatic amino acid, X3 is a hydrophobic or aromatic amino acid, and X4 is a hydrophobic or aromatic amino acid. Any amino acid, X5 is any amino acid, and a peptide linked by a disulfide bond can bind to eIF4E, thereby inhibiting its activity.
The peptide binds to the mRNA 5' cap binding site of eIF4E with high affinity, inhibits the activity of eIF4E, disrupts the binding of cap analog to cap binding site, and effectively inhibits the abnormal proliferation of cap-dependent translation in cancer.
Smart Images

Figure CN113646325B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Singapore Application No. 10201902892R filed on March 29, 2019, the contents of which are incorporated herein by reference in their entirety for all purposes. Technical Field
[0003] The present invention relates to a cell proliferation inhibitory peptide, and in particular, to a peptide that binds to elongation factor 4E (eIF4E). Background Art
[0004] The most frequently occurring cancer mutations are found in signal transduction pathways that feed into the translation machinery. These include well-studied and validated oncogenes such as MYC, RAS, and PIK3C. In addition, a broad range of translation initiation factors are often found to be amplified or misregulated in tumors. eIF4E (elongation initiation factor 4E) is frequently misregulated and overexpressed in most cancers and is closely associated with the upregulation of a large class of oncogenic-related proteins such as VEGF and c-MYC.
[0005] eIF4E plays an important role in translation initiation by interacting directly with the 5' cap structure of mRNA. All nuclear transcribed mRNAs have this 5' cap structure (m7GTP), which consists of a guanosine methylated at position 7 and linked to the first nucleotide of the mRNA via a 5' to 5' triphosphate bridge. The vast majority of eukaryotic mRNAs, including oncogenes, are translated in an eIF4E cap-dependent manner, and overexpression of eIF4E leads to increased translation of these genes. Therefore, the level of eIF4E activity needs to be controlled to prevent uncontrolled proliferation.
[0006] One way to regulate eIF4E levels and activity is through eIF4E binding proteins (4E-BPs) that modulate eIF4E activity. 4E-BPs negatively regulate eIF4E and share a common binding motif with eIF4G, which they use to directly bind to eIF4E and competitively displace the eIF4G scaffold protein. Displacement of eIF4G impairs assembly of the eIF4F complex on the 5' cap structure and impedes cap-dependent translation.
[0007] Therefore, there is a need to identify eIF4E binders with mechanisms of action different from those described above to circumvent emerging resistance mechanisms that have been reported for compounds targeting signaling pathways upstream of eIF4E involved in regulating protein synthesis. There is also a need to develop eIF4E binders for anticancer therapy. SUMMARY OF THE INVENTION
[0009] In one aspect, there is provided a method comprising the amino acid sequence CEX 1 GX2 X 3 X 4 X 5 C (SEQ ID NO: 1), wherein X 1 is an amino acid selected from the group consisting of threonine (T), methionine (M) or leucine (L); wherein X 2 is an amino acid selected from the group consisting of hydrophobic amino acids, aromatic amino acids, modified hydrophobic amino acids and modified aromatic amino acids; wherein X 3 is an amino acid selected from the group consisting of hydrophobic amino acids, aromatic amino acids, modified hydrophobic amino acids and modified aromatic amino acids; wherein X 4 is any amino acid; where X 5 is any amino acid; wherein the two cysteine residues are linked by a disulfide bond; and wherein the peptide binds to elongation initiation factor 4E (eIF4E).
[0010] In another aspect, there is provided a peptide as described herein for use as a medicament.
[0011] In another aspect, there is provided use of a peptide as described herein for treating a disease condition associated with dysregulation of cap-dependent translation.
[0012] In another aspect, a pharmaceutical composition comprising a peptide described herein and a pharmaceutically acceptable carrier is provided.
[0013] In another aspect, there is provided use of a peptide as described herein or a pharmaceutical composition as described herein in the manufacture of a medicament for treating a disease condition associated with dysregulation of cap-dependent translation.
[0014] In another aspect, provided is a method of treating a disease condition associated with dysregulation of cap-dependent translation in an individual in need thereof, comprising administering to the individual a peptide described herein or a pharmaceutical composition described herein.
[0015] definition
[0016] As used herein, the term "protein" or "peptide" refers to a polymeric form of amino acids. Proteins are understood to contain more amino acids than peptides, and "proteins" generally contain at least about 60 amino acids, while peptides generally contain 2 to about 60 amino acids. The amino acids in proteins or peptides can exist in D or L configurations or a combination of both configurations, and can be chemically or biochemically modified. The modification of amino acids can occur at the side chain or at the peptide bond connecting the amino acids. The peptide bond (-CONH-) can be modified to change the properties of the peptide bond. The peptide can also be chemically modified by adding covalently bound chemical groups, such as biotin, thiol, cysteine, amide, carboxyl, straight or branched alkyl, primary or secondary amine, lipid, phospholipid, fatty acid, cholesterol, etc. These chemical groups can be added to the N-terminus and / or C-terminus of the peptide or within the peptide. The peptide can also be modified by adding one or more other bonds, such as disulfide bonds, within the peptide between the N- and C-termini. The amine group at the N-terminus can also be chemically modified, such as by adding a cap by acetylation.
[0017] As used herein, the term "amino acid" refers to a 2 ) and carboxyl (-COOH) functional groups and side chains. Amino acids can be encoded by triplet codons (canonical amino acids) or variant codons (non-canonical amino acids) of nucleic acids. Amino acids can be characterized as α-amino acids or β-amino acids. In α-amino acids, the amine and carboxyl groups are attached to the first carbon. In β-amino acids, the amine and carboxyl groups are attached to adjacent carbons. Amino acids can also be characterized as D-amino acids (where the stereoscopic α carbon of the amino group has a D-configuration) or L-amino acids (where the stereoscopic α carbon of the amino group has an L-configuration). Amino acids can also be classified according to the properties of their side chains. For example, amino acids can be classified as acidic, basic, polar, hydrophobic, or aromatic, and amino acids can be classified into one or more categories. Aromatic amino acids include phenylalanine, tryptophan, tyrosine, and histidine. Hydrophobic amino acids include glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), proline (Pro), phenylalanine (Phe), methionine (Met) and tryptophan (Trp). Polar amino acids include serine (Ser), threonine (Thr), cysteine (Cys), asparagine (Asn), glutamine (Gln) and tyrosine (Tyr). Basic amino acids include arginine (Arg), lysine (Lys) and histidine (His), and acidic amino acids include aspartic acid or aspartate (Asp) and glutamic acid or glutamate (Glu).
[0018] The amino acids used herein may be naturally occurring, non-naturally occurring or synthetic. The amino acids used herein may also be modified by substituting one or more groups on the side chain.
[0019] Table 1: Amino Acids
[0020]
[0021]
[0022] The terms "modified," "modified," or grammatical variations thereof as used herein in the context of a modified amino acid refer to an amino acid in which one or more groups on the side chain are substituted. One or more of the following groups may be substituted: alkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halogen, carboxyl, haloalkyl, haloalkynyl, hydroxy, alkoxy, thioalkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino, dialkylamino, alkenylamino, alkynylamino, acyl, alkenoyl, alkynyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocyclooxy, heterocycloamino, haloheterocycloalkyl, alkylsulfinyl, alkylcarbonyloxy, alkylthio, acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, cyano, cyanate, isocyanate, -C(O)NH(alkyl) and -C(O)N(alkyl) 2 .
[0023] As used herein, the term "alkyl" includes within its meaning monovalent ("alkyl") and divalent ("alkylene") straight or branched chain saturated aliphatic groups having 1-10 carbon atoms, for example, having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.
[0024] The term "alkenyl" includes within its meaning monovalent ("alkenyl") and divalent ("alkenylene") straight or branched chain unsaturated aliphatic hydrocarbon groups having 2-10 carbon atoms, for example, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, and having at least one double bond in the E, Z, cis or trans stereochemistry, as applicable, at any position in the alkyl chain.
[0025] As used herein, the term "alkynyl" includes within its meaning monovalent ("alkynyl") and divalent ("alkynylene") straight or branched chain unsaturated aliphatic hydrocarbon groups having 2-10 carbon atoms and having at least one triple bond anywhere in the carbon chain.
[0026] The term "cycloalkyl" as used herein refers to a cyclic saturated aliphatic group and includes within its meaning monovalent ("cycloalkyl") and divalent ("cycloalkylene") saturated, monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon groups having 3-10 carbon atoms, for example, having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.
[0027] The term "cycloalkenyl" as used herein refers to a cyclic unsaturated aliphatic group and includes within its meaning monovalent (cycloalkenyl) and divalent (cycloalkenylene) monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon groups having 3-10 carbon atoms and, if applicable, at least one E, Z, cis or trans stereochemical double bond at any position of the alkyl chain. Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclopentenyl, cyclohexenyl, etc.
[0028] As used herein, the term "heterocycloalkyl" includes within its meaning monovalent ("heterocycloalkyl") and divalent ("heterocycloalkylene") saturated, monocyclic, bicyclic, polycyclic or fused hydrocarbon groups having 3-10 ring atoms, wherein 1-5 of the ring atoms are heteroatoms selected from O, N, NH or S. Examples include pyrrolidinyl, piperidinyl, quinuclidinyl, azetidinyl, morpholinyl, tetrahydrothienyl, tetrahydrofuranyl, tetrahydropyranyl, and the like.
[0029] The term "heterocycloalkenyl" as used herein includes within its meaning monovalent (heterocycloalkenyl) and divalent (heterocycloalkenylene) saturated, monocyclic, bicyclic, polycyclic or fused hydrocarbon groups having 3-10 ring atoms and having at least 1 double bond, wherein 1-5 of the ring atoms are heteroatoms selected from O, N, NH or S.
[0030] As used herein, the term "heteroaromatic group" and variations such as "heteroaryl" or "heteroarylene" include within their meaning monovalent ("heteroaryl") and divalent ("heteroarylene") mononuclear, polynuclear, conjugated and fused aromatic groups having 6-20 atoms, wherein 1-6 atoms are heteroatoms selected from O, N, NH and S.
[0031] As used herein, the term "heteroatom" or variations such as "hetero-" refers to O, N, NH, and S.
[0032] The term "alkoxy" as used herein refers to a straight chain or branched chain alkoxy group.
[0033] The term "amino" as used herein in the context of substitution refers to -NR a R b A group of the form R a and R bare individually selected from the group including, but not limited to, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted aryl.
[0034] As used herein, the term "aromatic group" or variations such as "aryl" or "arylene" refers to monovalent (aryl) and divalent (arylene) mononuclear, polynuclear, conjugated and fused aromatic hydrocarbons having 6-10 carbon atoms.
[0035] As used herein, the term "aralkyl" includes within its meaning monovalent ("aryl") and divalent ("arylene") mononuclear, polynuclear, conjugated and fused aromatic hydrocarbon groups attached to a divalent saturated, straight chain and branched alkylene group.
[0036] As used herein, the term "heteroaralkyl" includes within its meaning monovalent ("heteroaryl") and divalent ("heteroarylene") mononuclear, polynuclear, conjugated and fused aromatic hydrocarbon groups attached to divalent saturated, straight chain and branched chain alkylene groups.
[0037] As used herein, the term "halogen" or variations such as "halide" or "halo" refers to fluorine, chlorine, bromine, iodine, and cyanide halides.
[0038] As used herein, the term "equilibrium dissociation constant" or "dissociation constant" (K d ) is a measure of the strength of binding between two molecules, such as a protein and its ligand. The smaller the dissociation constant, the tighter the two molecules bind, and the higher the affinity between the two molecules.
[0039] As used herein, the term "inhibit" in the context of eIF4E activity means that the level of biological activity of eIF4E is disrupted, reduced, or absent compared to the level of activity of eIF4E that is not inhibited.
[0040] In the context of peptides or proteins, the terms "macrocycle" and "macrocyclic" refer to cyclic peptides, which are polypeptide chains containing a cyclic sequence of bonds. This can be achieved by a linkage between the amino and carboxyl termini of the peptide, such as in cyclosporin; between the amino terminus and a side chain, such as in bacitracin; between the carboxyl terminus and a side chain, such as in colistin; or between two side chains or more complex arrangements, such as in amanitin.
[0041] The term "pharmaceutical composition" as used herein refers to a mixture of one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs with other chemical components, such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compound to an organism.
[0042] The term "pharmaceutically acceptable carrier" as used herein refers to a medium generally accepted in the art for delivering a biologically active agent (i.e., an inhibitor disclosed alone or in combination with any disclosed compound in the context of the specification) to a mammal, such as a human. Such carriers are generally formulated according to many factors determined and considered within the purview of a person of ordinary skill in the art. These factors include, but are not limited to, the type and nature of the active agent to be formulated; the individual to whom the composition containing the pharmaceutical agent will be administered; the intended route of administration of the composition; and the therapeutic indications for which it is intended. Pharmaceutically acceptable carriers include aqueous and non-aqueous liquid media, as well as various solid and semi-solid dosage forms. In addition to the active agent, such carriers may include many different ingredients and additives, and such additional ingredients are included in the formulation for a variety of reasons, such as the stability of the active agent known to those of ordinary skill in the art. Non-limiting examples of pharmaceutically acceptable carriers are hyaluronic acid and its salts and microspheres (including, but not limited to, poly (D, L) -lactide - co-glycolic acid copolymer (PLGA), poly (L-lactic acid) (PLA), poly (caprolactone) (PCL) and bovine serum albumin (BSA)). As used herein, the term "cancer" refers to any of a number of diseases characterized by uncontrolled abnormal proliferation of cells, the ability of affected cells to spread locally or to other parts of the body through the bloodstream and lymphatic system (i.e., metastasis), and any of a number of characteristic structural and / or molecular features. Examples of cancer include, but are not limited to, breast cancer, bronchial cancer, colon cancer, colorectal cancer, liver cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, pancreatic cancer, head and neck cancer, stomach cancer, and bladder cancer, non-Hodgkin's lymphoma, leukemia, neuroblastoma, melanoma, glioma, or glioblastoma.
[0043] BRIEF DESCRIPTION OF THE DRAWINGS
[0044] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and accompanying drawings, in which:
[0045] Figure 1 Next generation sequencing (NGS) phage sequencing results and fluorescence polarization competition experiments are shown. NGS enhanced phage display screening against eIF4E was performed using the C7C library (available from NEB). C7C = disulfide constrained cyclic peptide displayed on M13 phage pili. Figure 1 A shows that a unique and novel motif interacting with eIF4E was identified, in contrast to peptide interaction motifs typically isolated by screening a linear 12mer library. Figure 1B shows the binding sites identified using fluorescence polarization experiments. The upper panel shows that the C7C peptide cannot displace a fluorescently labeled peptide containing a peptide interaction motif. This motif is present in the protein interaction partners of eIF4E->4E-BPs (1, 2, and 3) and eIF4G1. The lower panel shows that the C7C macrocycle EE-02 can displace fluorescently labeled m7GTP.
[0046] Figure 2 Shown is a tryptophan quenching experiment. This figure demonstrates how m7GTP and EE-02 have very different characteristics, which highlights that they can bind in different binding conformations. PHAGSOL is a phage-derived peptide identified to interact with the eIF4G binding site on eIF4E - containing a canonical peptide interaction motif.
[0047] Figure 3 shows the structure of the eIF4E cap-binding site in complex with or without m7GDP. Figure 3A Comparison of the m7GDP-bound eIF4E structure (left) and the unbound structure (right) is shown. 7 In the case of GDP, the indole side chains of W56 and W102 insert into the guanine ring of the nucleotide. E103 of eIF4E forms 2 hydrogen bonds recognizing the guanine ring. In addition, the methyl group present on N7 of the guanine ring induces the formation of a quaternary amine, thereby conferring a delocalized positive charge on the ring system. This leads to the formation of cation-π interactions with W56 and W102, further stabilizing the bound conformation. The diphosphate tail of m7GDP is recognized and forms electrostatic interactions with R157, K159 and K162. Residue R112 further recognizes the phosphate moiety via several structured water molecules. This conformation is referred to as the "closed" conformation. When eIF4E is unbound, distinct conformational changes occur around the region responsible for binding the N7 methyl-substituted guanine moiety. These changes are the rotation of W102, the movement of the loop containing W56 and the rotation of E103 out of the cap binding site. This conformation is referred to as the "open" state. Figure 3B The locations of the canonical peptide and cap-binding sites on eIF4E are indicated. Figure 3C Surface representations of the m7GDP-bound eIF4E and 'apo' eIF4E structures are shown, demonstrating clear structural differences in the shape and size of the cap-binding site between the two states.
[0048] Figure 4 shows a comparison of the structures of eIF4E bound to EE-02 or m7GDP. Figure 4A Surface representation of EE-02-bound eIF4E is shown, demonstrating that the shape and size of its cap-binding site are similar to those of 'apo' eIF4E and highlighting the differences in the cap site of eIF4E bound to m7GDP. Figure 4BComparison of the structure of EE-02-bound eIF4E with that of m7GDP is shown. The conformation of EE-02-bound eIF4E is very similar to the "apo" structure of eIF4E. E3 of EE-02 interacts directly with R112, M4 forms a hydrogen bond with S92 of eIF4E on the back of the cap-binding site, while residues F6 and F7 form hydrophobic interactions. Residues W56 and W102, which are responsible for recognition of the guanine ring system, are swung out of the cap-binding site. E103, which forms an H-bond with m7GDP, also swung out of the cap-binding site and is not involved in the interaction of EE-02 with eIF4E. Furthermore, in contrast to m7GDP, EE-02 does not directly interact with the residues that form the diphosphate binding pocket (R157, K159, and K162).
[0049] Figure 5 Key interactions made by conserved residues of the interaction motif identified by NGS phage sequencing in the crystal structure are shown. Key hydrogen bonds formed by EE-02 with eIF4E and itself are also highlighted.
[0050] All images above are based on real XTAL of EE-02 in complex with eIF4E TM structure. DETAILED DESCRIPTION OF THE INVENTION
[0052] In a first aspect, the present invention relates to a method comprising the amino acid sequence CEX 1 GX 2 X 3 X 4 X 5 C (SEQ ID NO: 1), wherein X 1 is an amino acid selected from the group consisting of threonine (T), methionine (M) or leucine (L); wherein X 2 is an amino acid selected from the group consisting of hydrophobic amino acids, aromatic amino acids, modified hydrophobic amino acids and modified aromatic amino acids; wherein X 3 is an amino acid selected from the group consisting of hydrophobic amino acids, aromatic amino acids, modified hydrophobic amino acids and modified aromatic amino acids; wherein X 4 is any amino acid; where X 5 is any amino acid; wherein the two cysteine residues are linked by a disulfide bond; and wherein the peptide binds to elongation initiation factor 4E (eIF4E).
[0053] In one embodiment, the peptide comprises the amino acid sequence CEX 1 GFFX 4 X 5 C (SEQ ID NO: 13).
[0054] The peptides of the present invention can be isolated from cells or reaction vessels by methods known in the art. The peptides of the present invention can also be purified by methods known in the art.
[0055] In some embodiments, the peptides of the present invention can be chemically synthesized and then isolated or purified. For example, the peptides of the present invention can be synthesized by fluorenylmethoxycarbonyl protecting group strategy (FMOC) solid phase chemical synthesis. Then, iodine-mediated oxidation is performed to form disulfide bonds that constrain the peptide.
[0056] In one embodiment, the peptide binds to eIF4E at the mRNA 5' cap binding site. The peptide binds to the mRNA 5' cap binding site of eIF4E with high affinity. In one embodiment, the peptide binds to the mRNA 5' cap binding site of eIF4E with a dissociation constant (K) of less than about 250 nM, less than about 200 nM, less than about 150 nM, less than about 100 nM, less than about 50 nM. d ) binds to the mRNA 5' cap binding site. In one embodiment, the peptide binds to the mRNA 5' cap binding site with a K of less than 100 nM. d Binds to eIF4E.
[0057] The peptide may interact with the 5' cap binding site by a mechanism or mode that is different from the interaction of the cap analog (m7GDP) with the 5' cap binding site.
[0058] In one embodiment, the peptide binds to the eIF4E cap binding site in a conformation different from that of m7GDP. In another embodiment, the binding of the peptide to eIF4E disrupts the binding of the cap analog to the cap binding site. This in turn inhibits the activity of eIF4E.
[0059] In one embodiment, the peptide binds to eIF4E in an open conformation. An "open conformation" refers to the conformation of the phenylalanine at positions 102 and 56 (W102 and W56) when they do not interact with m7GDP and swing out of the binding site. In contrast, a "closed conformation" refers to the conformation of W102 and W56 when W102 and W56 swing back into the cap binding site and m7GDP is sandwiched between them.
[0060] In one embodiment, binding of the peptide to eIF4E inhibits eIF4E activity.
[0061] It is generally understood that a disulfide bond between two cysteine residues cyclizes a peptide.
[0062] It will be appreciated that the cyclized peptides of the invention interact with eIF4E and that when the disulfide bonds are reduced, the interaction is abolished. The peptides of the invention represent the key motifs responsible for this interaction with eIF4E and the necessity of constraining the peptides.
[0063] In one embodiment, the present invention comprises the amino acid sequence CEX 1 GX 2 X 3 X 4 X 5 The peptide C (SEQ ID NO: 1) can be 1 In another embodiment, X 2 and X 3 Independently selected from the group consisting of tyrosine (Y), phenylalanine (F) or modified phenylalanine.
[0064] Modified phenylalanine refers to phenylalanine in which one or more groups on the aromatic ring are substituted.
[0065] In another embodiment, X 4 and X 5 are independently glutamine (Q), aspartic acid (D), alanine (A), lysine (K), glycine (G) or leucine (L).
[0066] In yet another embodiment, X 5 In yet another embodiment, X 5 It is D-aspartic acid or L-aspartic acid.
[0067] In some embodiments, the peptide may comprise one or more additional amino acid residues at the N-terminus and / or C-terminus. These one or more additional amino acid residues may be from a phage or a portion of a phage on which the peptide is displayed. In one embodiment, the peptide comprises an additional alanine residue at the N-terminus and an additional glycine residue at the C-terminus. Alanine and glycine residues are non-random parts of the phage, which are present outside the random parts that make up the phage library.
[0068] In one embodiment of the present invention, the peptide comprises an amino acid sequence selected from the group consisting of ACEMGFFQDCG (SEQ ID NO:2), CEMGFFQDCG (SEQ ID NO:3), ACEMGFFADCG (SEQ ID NO:4), ACEMGFFKDCG (SEQ ID NO:5), ACEMGFFLDCG (SEQ ID NO:6), CEMGFFADC (SEQ ID NO:7), ACEMGYFQDCG (SEQ ID NO:28) and ACEMGFYQDCG (SEQ ID NO:32).
[0069] In another embodiment, the peptide consists of an amino acid sequence selected from the group consisting of ACEMGFFQDCG (SEQ ID NO:2), CEMGFFQDCG (SEQ ID NO:3), ACEMGFFADCG (SEQ ID NO:4), ACEMGFFKDCG (SEQ ID NO:5), ACEMGFFLDCG (SEQ ID NO:6), CEMGFFADC (SEQ ID NO:7), ACEMGYFQDCG (SEQ ID NO:28) and ACEMGFYQDCG (SEQ ID NO:32).
[0070] In another embodiment, the peptide consists of the amino acid sequence CEMGFFADC (SEQ ID NO: 7).
[0071] The peptides of the invention may be conjugated to one or more additional compounds. In one embodiment, the peptides are conjugated to one or more additional peptides.
[0072] In some embodiments, one or more additional peptides are cell penetrating peptides. Cell penetrating peptides (CPPs) are peptides that promote cellular uptake of peptides. CPPs can be divided into synthetic, chimeric or protein-derived, or can be divided into cationic, hydrophobic or amphipathic. Examples of cell penetrating peptides include, but are not limited to, polyarginine, transactivating transcription activator (TAT), transporter (transportan) and penetratin (penetratin).
[0073] The present invention also relates to the use of the peptides described herein as medicaments.
[0074] In one embodiment, the peptides described herein are used to treat disease conditions associated with dysregulation of cap-dependent translation.
[0075] The present invention also provides pharmaceutical compositions comprising the peptides described herein.
[0076] The present invention also provides the use of a peptide or pharmaceutical composition as described herein in the manufacture of a medicament for treating a disease condition associated with dysregulation of cap-dependent translation.
[0077] In one embodiment, the cap-dependent translational dysregulation is the result of aberrant eIF4E expression or aberrant eIF4E activity.
[0078] In some embodiments, abnormal eIF4E expression is eIF4E overexpression. In other embodiments, abnormal eIF4E activity is an increase in eIF4E activity above physiological levels. It is generally understood that overexpression of eIF4E means an increase in the expression of eIF4E compared to normal physiological expression levels. It is also generally understood that an increase in eIF4E activity can be mediated by an increase in the phosphorylation of 4E-BP1.
[0079] In one embodiment, the disease condition associated with overexpression of eIF4E is cancer.
[0080] In another embodiment, the disease condition associated with dysregulated cap-dependent translation is an infectious disease that hijacks cap-dependent translation. Examples of such diseases include, but are not limited to, influenza and viral diseases caused by coronaviruses.
[0081] In yet another embodiment, the disease condition associated with dysregulation of cap-dependent translation is Fragile X syndrome or autism.
[0082] The present invention also provides a vector comprising a nucleic acid sequence encoding a peptide as described herein. The present invention also provides a host cell transfected with a vector as described herein, wherein the host cell expresses a peptide as described herein.
[0083] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like are to be interpreted broadly and not restrictively. Furthermore, the terms and expressions used herein have been used as descriptive and not restrictive terms, and no equivalents of the features shown and described, or portions thereof, are intended to be excluded when such terms and expressions are used, but it is recognized that various modifications may be made within the scope of the claimed invention. Therefore, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modifications and variations of the invention embodied therein as disclosed herein may be resorted to by those skilled in the art, and such modifications and variations are deemed to be within the scope of the present invention.
[0084] The invention has been described broadly and generically herein. Each narrower class and subgeneric grouping falling within the general disclosure also forms part of the present invention. This includes the general description of the invention with a proviso or negative limitation removing any subject matter therefrom, whether or not the removed material is specifically cited herein.
[0085] Other embodiments are within the appended claims and the following non-limiting examples.In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0086] Experimental Section
[0087] Non-limiting examples and comparative examples of the present invention are further described in more detail by referring to specific examples, which should not be construed as limiting the scope of the present invention in any way.
[0088] method
[0089] Phage display and fluorescence competition assay
[0090] Fluorescence anisotropy determination and K d Determination
[0091] General assay design
[0092] The 50 nM carboxyfluorescein (FAM) labeled tracer peptide (KKRYSRDFLLALQK-(FAM)) (SEQ ID NO: 8) or 50 nM fluorescein labeled m 7 GTP-6-FAM titration of purified eIF4E. Tracer peptide and FAM-labeled m 7 GTP K d (dissociation constant) was determined by fitting their respective experimental titrations to a 1:1 binding model by using the following equation:
[0093]
[0094] where [P] is the protein concentration, [L] is the labeled peptide concentration, r is the measured anisotropy, and r 0 is the anisotropy of the free peptide, r b is the anisotropy of the eIF4E-tracer peptide complex, [L] t is the total concentration of FAM-labeled peptides, [P] t is the total concentration of eIF4E. K for the assay of the interaction between the tracer peptide and eIF4E d is 50.3nM, and m 7 K of GTP-6-FAMd Both were later used in competition experiments to determine K d .
[0095] The apparent K of various molecules was then determined by competitive anisotropy experiments. d value.
[0096] Binding assessment at the 4E:4G site
[0097] Titrations were performed in which the concentration of eIF4E was kept constant at 200 nM and the concentration of the labeled peptide was kept constant at 50 nM. The competitor molecule was then titrated against the complex of the FAM-labeled peptide and eIF4E. The apparent K was determined by fitting the experimental data to the equation shown below d value:
[0098]
[0099] d=K d1 +K d2 +[L] s t +[L] t -[P] t
[0100] e=([L] t -[P] t )K d1 +([L] s t -[P] t )K d2 +K d1 K d
[0101] f=-K d1 K d2 [P] t
[0102]
[0103] [L] st and [L] t represent the labeled ligand and total unlabeled ligand input concentrations, respectively. K d2 is the dissociation constant for the interaction between the unlabeled ligand and the protein. In all types of competition experiments, it is assumed that [P] t >[L] st Otherwise, a large amount of free labeled ligand will always be present and interfere with the measurement. K d1 is the apparent K of the labeled peptide used in each experiment dThe tracer peptide was dissolved in 1 mM DMSO and diluted into the assay buffer. The readings were performed using an Envision Multi-label Reader (PerkinElmer). The assay was performed in PBS (2.7 mM KCl, 137 mM NaCl, 10 mM Na 2 HPO 4 and 2 mM KH 2 PO 4 (pH 7.4)), 3% DMSO (v / v) and 0.1% Tween 20 buffer. All titrations were performed in triplicate. Curve fitting was performed using Prism 4.0 (GraphPad).
[0104] Cap analog binding assessment
[0105] Titrations were performed in which the concentration of eIF4E was kept constant at 250 nM and the concentration of labeled m7GTP was kept constant at 50 nM. The competitor molecule was then titrated against the complex of FAM-labeled m7GTP and eIF4E. The apparent K was determined by fitting the experimental data to the equation shown below d value:
[0106]
[0107] d=K d1 +K d2 +[L] s t +[L] t -[P] t
[0108] e=([L] t -[P] t )K d1 +([L] s t -[P] t )K d2 +K d1 K d
[0109] f=-K d1 K d2 [P] t
[0110]
[0111] [L]st and [L]t represent the input concentrations of labeled ligand and total unlabeled ligand, respectively. d2 is the dissociation constant for the interaction between the unlabeled ligand and the protein. In all types of competition experiments, it is assumed that [P] t>[L] st Otherwise, a large amount of free labeled ligand will always be present and interfere with the measurement. K d1 is the apparent K of the labeled peptide used in the respective experiment d FAM-labeled m7GTP was provided at 1 mM in Tris-HCL pH 7.5 (Jena Biosciences) and diluted into the assay buffer. Readings were performed using an Envision Multi-label Reader (PerkinElmer). 2 HPO 4 and 2 mM KH 2 PO 4 Experiments were performed in 5% DMSO (v / v) and 0.1% Tween 20 buffer (pH 7.4). All titrations were performed in triplicate. Curve fitting was performed using Prism 4.0 (GraphPad).
[0112] NGS-enhanced phage display
[0113] Selection of C7C disulfide-constrained phage library against eIF4E
[0114] Phage library
[0115] The C7C phage library was purchased from New England Biolabs. This library is a combinatorial library of random peptides with a disulfide-constrained loop fused to the minor capsid protein (pIII) of M13 phage. The displayed peptides are expressed at the N-terminus of pIII in the form of AC-X7-CGGGS (X = random amino acid) (SEQ ID NO: 9). The two cysteines spontaneously form a disulfide bridge under oxidative conditions to constrain the peptide sequence. The library consists of approximately 1 x 10 9 The electroporation sequence is composed of a single (i.e., unique) sequence.
[0116] eIF4E immobilization and phage selection
[0117] A 96-well polystyrene plate was coated with a streptavidin solution (150 μl per well, 20 μg / ml, and incubated overnight at 4°C. 3. The coating solution was then removed. The wells on the 96-well plate were then washed 4 times with 200 μl of binding buffer (50 mM Tris-HCl, 150 mM NaCl (pH 7.4)). After washing, 150 μl of biotin-labeled protein (5-10 mg / ml in binding buffer) was loaded into the wells. The streptavidin control wells were loaded with only 150 μl of binding buffer. The 96-well plate was then incubated at room temperature for 15 min, and the contents were then poured out. The wells were then washed 4 times with 200 μl of binding buffer. After washing, the wells were blocked with 200 μl of blocking buffer ((50 mM Tris-HCl, 150 mM NaCl (pH 7.4). 0.01% BSA (w / v), 0.1% The wells were blocked with Tween20 (v / v) for 30 min at room temperature. 12 The phage library was prepared at 100 pfu / ml and incubated at room temperature for 30 min. The blocking buffer was then poured out from the 96-well plate and 100 μl of the phage library was distributed between the wells, with about 10 pfu / ml per well. 11 pfu. The plate was then incubated at room temperature for 1 hour. Unbound phage was then removed by pipetting from each well. The wells were then washed 8 times with 200 μl of wash buffer. The bound phage was then incubated with 100 μl of elution buffer (0.2 M glycine-HCl, pH 2.2 + 0.1% (w / v) BSA) at room temperature for 9 min. The supernatant containing the eluted phage was then transferred separately to a separate tube containing 15 μl of neutralization buffer (1 M Tris-HCl, pH 9.1).
[0118] Phage amplification and M13 DNA isolation
[0119] Escherichia coli (ER 2738 strain) cultured overnight was diluted 100 times and 3 ml of the culture was distributed to each 15 ml culture tube. The culture was incubated at 37C for 4-4.5 hours while shaking at 230 rpm. After incubation, the tube was centrifuged at 4000 rpm for 15 min at 4°C to precipitate bacterial cells. In order to precipitate phage, the supernatant in each tube was poured into a separate 5 ml falcon tube containing MP buffer (30 μl, 100x) and vortexed. 700 μl of precipitated phage solution was loaded into a separate Qiagen centrifugal column and centrifuged at 8000 rpm for 30 seconds. The resulting flow-through was discarded. After this step, 700 μl of buffer PB was applied to each centrifugal column and centrifuged at 8000 rpm for 30 s. The flow-through was discarded again and this step was repeated. After completing this step, 700 μl of buffer PE was added to each centrifugal column. Spin each column at 8000 rpm for 30 s and discard the flow-through in the collection tube. Repeat the centrifugation step, but extend the spin to 2 min to remove any residual PE buffer. Transfer the spin column to a fresh 1.5 ml Eppendorf tube. Elute the DNA into each column by adding EB buffer (50 μl), then wait for 1 min and centrifuge at 800 rpm for 30 s. For more details on buffers and procedures, refer to the m13QIAprep Spin M13 Kit Manual (Qiagen, Ltd).
[0120] MP Buffer Formulation
[0121] 1. Dissolve 3.3g of citric acid monohydrate in 3ml of high-purity water at room temperature (21°C)
[0122] 2. Incubate the solution for 5 min by stirring at 200 rpm
[0123] 3. Filter the solution through a 0.2 μm sterile filter using a syringe to obtain a final volume of 6 ml of Buffer MP.
[0124] Barcoding and library amplification
[0125] Fifteen barcoded reverse primers were designed with adaptors compatible with Illumina sequencing. Library DNA was PCR amplified using barcoded primers flanking the variable regions. Each eluate of ssM13 phage DNA was uniquely coded. Briefly, 1× Buffer, 200 μM each dNTP, 1.5 mM MgCl 2 , 0.5 μM forward primer, 0.5 μM barcoded reverse primer and one unit Library DNA (15 samples, 50 ng each) was amplified using a high-fidelity DNA polymerase in a total volume of 25 μL. PCR was performed using the following thermocycler program: 95°C for 30 s, followed by 95°C for 10 s, 60.5°C for 15 s, and 72°C for 30 s for 25 cycles, followed by a final extension at 72°C for 5 min, followed by a hold at 4°C. dsDNA fragments from PCR were quantified by running a 2% (w / v) agarose gel in Tris-borate-EDTA buffer at 100 volts for approximately 45 min using a low molecular weight DNA ladder as a standard (NEB, #N3233S). dsDNA fragments (15 samples, 40 ng each) were pooled together and SizeSelectTM 2% agarose gel (Invitrogen, #G6610-02) was used for purification. The desired band corresponding to 121 bp was collected with RNase-free water using a reference ladder. The DNA concentration of the purified DNA was determined using PicoGeen (Thermofisher) according to the manufacturer's instructions.
[0126] DNA template preparation and Illumina sequencing (NextSEQ)
[0127] Sequencing was performed by AXIL Scientific. Pooled DNA was hybridized to an Illumina chip, bridge amplified, and then sequenced using Illumina technology. 500Mid Output Kit (150 cycles) (Cat. No. FC-404-1001) and The 500 / 550 Mid Output Kit v2 (150 cycles) (Cat. No. FC-404-2001) was used to sequence reads in both forward (F) and reverse (R) directions. FASTQ files were processed using paired-end analysis using an in-house developed python script.
[0128] Differential enrichment and sequence ID generation
[0129] Analyze and parse FASTQ files to separate sequences into their respective selections by relevant barcodes.Then determine the frequency of each unique peptide sequence encoded by the variable domain and normalize by the total number of sequences in the selection.For each repetition, such as eIF4E repeats 1-3 and streptavidin controls 1-3, repeat the process.Sequences not observed in a specific repetition are designated as zero for normalized frequency.The enrichment ratio of each sequence is determined by dividing the average normalized frequency of a specific sequence (from the repeat set for the selection) by the frequency in the control repeat set.Since the denominator cannot be zero when taking the ratio, before calculating the ratio, sequences that do not appear in all three repetitions are assigned an arbitrary value (e.g., 0.0001).Use unequal variance Student's t-test (Welch test) to evaluate the significance (p value) of the ratio.Then generate a heat map for any determined value of p value and enrichment ratio.The typical values used are p value <0.1 and ratio>5.0.Sequences are sorted by their enrichment values in the heat map. The heatmap identifies sequences isolated from a particular selection that are significantly increased in abundance relative to sequences isolated from a control selection (or an unrelated selection group). Sequence logos were generated from the enriched sequences using WebLogo (https: / / weblogo.berkeley.edu / ).
[0130] Tryptophan quenching assay
[0131] use Tryptophan quenching experiments were performed using a multiplate reader and black matte 96-well plates. Samples (100 μl) were prepared with 1 μM purified eIF4E against a series of concentrations of the following compounds: 7 GTP, PHAGESOL (KKRYSRDQLVAL) (SEQ ID NO: 10) or EE-02. The concentration range tested was 0.01-20 μM. The samples were excited with 290 nm UV light to minimize the effect of tyrosine fluorescence. Tryptophan was measured at an emission wavelength of 355 nm.
[0132] Crystallization of eIF4E:EE-02
[0133] crystallization
[0134] The eIF4E:EE-02 complex was crystallized by vapor diffusion using the sitting drop method. The crystallization drop contained eIF4E and EE-02 at concentrations of 150 μM and 300 μM, respectively. The sitting drop was set up in a 48-well Intelli-Plate (Hampton Research) and 1 μl of protein sample was mixed with 1 μl of mother well solution. Crystals were grown for one week in 0.2 M ammonium sulfate 0.1 M Tris trisodium acetate pH 4.6 and 25% PEG4000. To collect X-ray data at 100 K, the crystals were transferred to an equivalent mother liquor solution containing 20% (v / v) glycerol and then flash frozen in liquid nitrogen.
[0135] Data collection and refinement
[0136] Data were collected at the Australian Synchrotron at beamline MX1 using a CCD detector. The crystal diffracted to The initial phase of the binary complex crystal of eIF4E was solved by molecular replacement and the program PHASER using the human eIF4E structure with water and other bound components removed (PDB accession code: 4BEA) as a search model. The starting model was subjected to rigid body refinement followed by iterative cycles of manual model building in Coot and restrained refinement in Refmac 6.0.
[0137] General approach
[0138] Expression, refolding and purification of eIF4E for fluorescence polarization (FP), surface plasmon resonance (SPR) and crystallography Experiment)
[0139] Rossetta pLysS competent bacteria were transformed with the pET11d expression plasmid containing the full-length eIF4E clone. Both materials were provided by Cyclacel Ltd., Dundee. Cells expressing the full-length eIF4E construct were grown in LB medium at 37°C to an OD of 600 The pH was about 0.6, and eIF4E induction was started with 1 mM IPTG. The culture was immediately placed in a shaker-incubator at 37°C for 3 h. The cells were harvested by centrifugation and the cell pellet was resuspended in 50 mM Tris pH 8.0, 10% sucrose and then sonicated.
[0140] The sonicated samples were centrifuged at 17,000 g for 10 min at 4 °C. The resulting pellet was resuspended in Tris / Triton buffer (50 mM Tris pH 8.0, 2 mM EDTA, 100 mM NaCl, 0.5% Triton X-100). The samples were then centrifuged at 25,000 g for 15 min at 4 °C and the pellet was resuspended in Tris / Triton buffer. After re-centrifugation, the remaining pellet was dissolved in 6 M guanidine hydrochloride, 50 mM Hepes-KOH pH 7.6, 5 mM DTT. The protein concentration of the sample was then adjusted to 1 mg / mL.
[0141] The denatured protein was refolded into a refolding buffer consisting of 20 mM Hepes-KOH, 100 mM KCl and 1 mM DTT by 1 / 10 dilution. The refolded protein was concentrated and desalted into refolding buffer using an Amersham PD10 column. The eIF4E protein sample was run on a monoQ column and eluted with a 1 M KCl gradient. eIF4E eluted as a sharp peak at approximately 0.3 M KCl.
[0142] Surface plasmon resonance (for structure activity relationship (SAR) tables)
[0143] For peptide stock solutions, compounds were dissolved in 100% DMSO to a concentration of 10 mM; peptide stock solutions were further diluted into DMSO and / or running buffer immediately prior to analysis. Running buffer consisted of 10 mM Hepes pH 7.6, 0.15 M NaCl, and 0.1% Tween 20. Peptide stock / DMSO diluted peptide solutions were diluted into 1.03× running buffer to prepare peptide solutions with a final DMSO concentration of 3%. Working concentrations of peptides were achieved by further diluting samples into running buffer containing 3% DMSO. Surface plasmon resonance experiments were performed on a Biacore T100 machine.
[0144] Pure eIF4E was immobilized on a CM5 sensor chip. The CM5 chip was conditioned by injecting 100 mM HCL for 6 s, followed by injecting 0.1% SDS for 6 s and ending with an injection of 50 mM NaOH for 6 s at a flow rate of 100 μl / min. NHS (115 mg ml -1 ) and EDC (750 mg ml -1 ) at 10 μl min -1The sensor chip surface was activated for 7 min. Purified eIF4E was diluted to a final concentration of 0.5 μM with 10 mM sodium acetate buffer (pH 5.0), and m7GTP was present at a 2:1 ratio to stabilize eIF4E. The amount of eIF4E immobilized on the activated surface was controlled by varying the contact time of the protein solution, which was approximately 1000 RU. After protein immobilization, the protein was injected with 1 M ethanolamine (pH 8.5) for 7 min (10 μl min -1 ) to quench excess reactive succinimide ester groups.
[0145] Six buffer blanks were first injected to fully equilibrate the instrument, followed by a solvent calibration curve, followed by two further blank injections. The solvent calibration curve was set up by adding different amounts of 100% DMSO to 1.03x running buffer to generate a series of DMSO solutions (3.8%, 3.6%, 3.4%, 3.2%, 3%, 2.85%, 2.7% and 2.5%, respectively). The compound was injected for 60 s at a flow rate of 50 μl / min and the dissociation was monitored for 180 s. The data collection rate was 10 Hz. K ds The K values were determined using BiaEvaluation software (Biacore) and calculated from the response of the eIF4E-coated CM5 chip at equilibrium and from the kinetics of the dissociation and association phase data for each peptide. Both equilibrium and kinetic data were fitted to a 1:1 binding model. The K values for each individual peptide were determined from three separate titrations. d In each titration, at least two concentration points were replicated to ensure the stability and robustness of the chip surface.
[0146] GST affinity purification for biotinylated eIF4E
[0147] The full-length eIF4E was ligated into the GST fusion expression vector pGEX-4 (GE Lifesciences) by double digestion with BAMH1 and NDE1. The GST-tagged eIF4E fusion construct was then used to transform BL21 DE3 competent bacteria. The cells expressing the GST fusion construct were grown in LB medium at 37°C to an OD of 600The cell mass was about 0.6 and induced at 1 mM at room temperature. The cells were harvested by centrifugation, the cell mass was resuspended in 50 mM Tris pH 8.0, 10% sucrose, and then sonicated. The sonicated sample was centrifuged at 17,000 g for 60 min at 4 ° C. The supernatant was applied to a 5 ml FF GST column (Amersham) pre-equilibrated in a wash buffer (phosphate buffered saline, 2.7 mM KCL and 137 mM NaCL, pH 7.4) with 1 mM DTT. The column was then further washed with 6 volumes of wash buffer. eIF4E was then purified from the column by cleavage with Precission (GE Lifesciences) protease. 50 units of thrombin protease (in one column volume PBS with 1 mM DTT buffer) were injected onto the column. The cleavage reaction was allowed to proceed overnight at 4 ° C. The cleaved protein was then eluted from the column with wash buffer. Protein fractions were analyzed using SDS-PAGE gels and concentrated using a Millipore Centricon (10 kDa MWCO) concentrator. The eIF4E protein sample was then dialyzed into a buffer solution containing 20 mM Hepes-KOH, 100 mM KCl, and 1 mM DTT. The eIF4E protein sample was then passed through a monoQ column and eluted with a 1 M KCl gradient. eIF4E eluted as a sharp peak at approximately 0.3 M KCl. Protein concentration was determined using UV absorbance.
[0148] Sortase-mediated biotinylation of eIF4E for immobilization and (n) phage display
[0149] The biotin tag was incorporated into GS-eIF4E using a sortase-mediated ligation. In a ligation buffer (50 mMTris, 1500 mM NaCl, 10 mM TCEP (pH 8.0)), the following reagents were mixed in a volume of 1000 μl: 40 μM GS-eIF4E, 5 μM SrtA61-206-His6 (8M), 200 μM biotin-KGGGLPET-GG-OHse (Ac) -amide. The sample was incubated at room temperature for 4 hours. The labeling efficiency of 2 μl of the sample was analyzed by SDS-PAGE gel. After analysis, the reaction sample was then purified to remove all reaction components except eIF4E. The sample was resuspended with 50 μl of pre-washed His-Tag magnetic beads (Qiagen) and incubated on a roller at room temperature for 5 min. 7. The tube was placed on a magnet for 2 min, and the supernatant containing the biotinylated protein was then transferred to a fresh Eppendorf tube. Biotinylated proteins were dialyzed against 2L PBS using a Slide-A-Lyzer cassette (10k MWCO) (4 hours), then the buffer was changed to 50mM Tris, 150mM NaCl (pH 7.4) and dialyzed overnight. Protein concentration was measured. Protein samples were aliquoted and snap frozen.
[0150] result
[0151] A novel macrocyclic peptide that binds eIF4E at the cap-binding site
[0152] Phage display library was panned for N-terminally biotinylated eIF4E. The phage display library used consisted of 7 random amino acids constrained by a disulfide bond between two cysteine residues (ACXXXXXXXC–GGGS) (SEQ ID NO: 9), which was fused to the minor capsid protein (pIII) of M13 phage via a GGS linker. The library was commercially purchased from New England Biolabs (NEB). eIF4E was biotinylated by peptide ligation, whereby a biotin-labeled peptide (biotin-LPETGG) (SEQ ID NO: 37) was fused to the N-terminal glycine on eIF4E using a sortase. EIF4E with an N-terminal glycine was generated by purification using a GST tag and removal of the GST tag using thrombin. Biotinylated eIF4E was immobilized on a streptavidin-coated plate.
[0153] Next generation sequencing (NGS) enhanced phage display was performed by 3x selection for eIF4E and 3x control selection (for both Mdm2 and eIF4A). Selection was performed as described in the methods. Phage was isolated, amplified and sequenced using Illumina NextSEQ technology (see methods). An internal python script was used to analyze the data and identify a set of unique peptides with new eIF4E interaction motifs ( Figure 1 ).
[0154] The consensus motif identified consisted of CE-(T / M / L)-GFFXXC (SEQ ID NO: 11). X represents any amino acid. Parallel NGS enhanced phage selections were performed using a phage library consisting of random 12mer linear peptides (NEB) against eIF4E. However, this library only identified eIF4E well interacting binding motifs that interacted with the eif4g binding site on eIF4E. (YXRXXLΦ, Φ = any hydrophobic amino acid) (SEQ ID NO: 12).
[0155] Based on these initial results, it was predicted that the new peptide motif might interact with eIF4E through a different binding pose at the eIF4G binding site, the cap binding site, or elsewhere on the protein. The binding site was initially delineated on eIF4E using two types of competitive fluorescence polarization experiments, one with a FAM-labeled cap analog and the other with a FAM-labeled eIF4G1-derived peptide. Figure 1 These experiments confirmed that EE-02 (ACEMGFFQDCG) (SEQ ID NO: 2) ( Figure 1 ) was the most potent peptide of the group identified and confirmed that this novel interaction motif disrupts the binding of the cap analog to eIF4E.
[0156] The structure of EE_02 is significantly different from that of cap analogs consisting of guanine triphosphate molecules with a methyl substitution at the N7 position of the guanine ring. This directly suggests that macrocyclic peptides can interact with the cap binding site through very different mechanisms.
[0157] To confirm this hypothesis, tryptophan quenching experiments were performed in which EE-02, m7GTP, or eIF4G1-derived peptides were titrated against eIF4E ( Figure 2 ).
[0158] The PhageSol peptide produced significantly lower tryptophan quenching than the other titrants. This result was expected because only one tryptophan residue (W73) is located near the eIF4G binding site, especially compared to m7GTP / m7GDP, which binds in the cap binding site and inserts between two tryptophan residues (W56 and W102), thus resulting in significantly more quenching. However, EE-02, which also binds in the cap binding site, produces a significantly different signature than m7GTP / m7GDP. This difference suggests that the interaction of EE-02 with eIF4E occurs through a different mode and may be allosteric in how it affects the cap binding site.
[0159] To address this question, structural studies were performed and the crystal structure of EE-02 bound to eIF4E was successfully solved (Figures 3 and 4).
[0160] Structural studies showed that EE-02 interacts directly with the cap-binding site and does not insert between the tryptophan rings. This result explains the different curves observed in the tryptophan quenching experiments. In addition, the EE-02 macroloop binds to eIF4E without mimicking the phosphate tail or cation-π interactions generated by m7GDP (Figures 3, 4, and 5).
[0161] EE-02 interacts with eIF4E through four distinct pockets ( Figure 5 The macroloop itself forms the β-hairpin into the cap binding site, allowing residues E3, E4, F6, and F7 to project into the Figure 5 into the corresponding pockets shown.
[0162] Alanine scanning mutagenesis was also performed on EE-02 to confirm the key interactions identified in the crystal structure (Table 2).
[0163] Table 2: Alanine scanning mutagenesis of EE-02
[0164]
[0165]
[0166] K was determined using surface plasmon resonance (SPR) as described in the methods. d Alanine scanning confirmed that residues E3, M4, G5, F6, and F7 are all critical for binding to eIF4E. The sensitivity of G5 to substitution highlights its importance in allowing the formation of a β-hairpin with the correct geometry in the binding pocket. Substitution of Q8 with A did not affect binding. However, replacement of D9 with A resulted in a two-fold decrease in binding.
[0167] Table 3: Targeted mutagenesis at the E3 and M4 sites of EE-02
[0168]
[0169] E4 could not be replaced by D4, emphasizing the importance of the correct orientation of the carboxyl group to interact with R112 of eIF4E. Replacement of M4 with shorter and smaller aliphatic groups such as I and L resulted in loss of binding. M4 was also replaced with non-natural aliphatic amino acids norleucine and cyclobutylalanine, which are similar in size to methionine. However, the K values determined for these molecules against eIF4E were d This highlights the importance of the interaction between the sulfur atom and S92.
[0170] Table 4: Targeted mutagenesis of residue G5
[0171]
[0172] G5 was replaced with different amino acids (β-alanine (bA), sarcosine (Sar), P) to explore different stereochemical constraints around this position. All of these resulted in a significant reduction in macroloop binding to eIF4E, further highlighting the role of G5 in allowing β-hairpin formation and orienting the key interacting residues into their optimal position for binding to eIF4E.
[0173] Table 5: Targeted mutagenesis at positions F6 and F7 in EE-02
[0174]
[0175] By exploring ring substituents on F6 and F7, binding to eIF4E can be improved stepwise. Replacing F6 with Y6 or F7 with Y7 yielded two molecules (EE-30 and EE-35, respectively) that bind tighter than EE-02. These results suggest that these positions can be further explored to generate better binding analogs.
[0176] Table 6: Targeted mutagenesis at position Q8 in EE-02
[0177]
[0178] Position 8 of EE-02 does not show a strict preference for a specific residue. This correlates with the fact that it does not interact with eIF4E in the crystal structure. However, the slight decrease in binding of the G mutation suggests that a strategy for rigidification of this position could improve binding through an entropy reduction mechanism.
[0179] Table 7: Truncation studies on EE-02
[0180]
[0181] These studies aimed to discover the smallest macrocycle with the smallest molecular weight (MW) that could bind eIF4E. In addition, N-terminal capping of the macrocycle was investigated to identify the effects of acetylation and free amines on eIF4E binding. This led to the identification of EE-44, where non-library phage amino acid positions A1 and G11 could be removed and acetylation significantly reduced macrocycle binding. EE-44, due to its small MW and reduced size, is a more suitable starting point for the rational design of macrocycles with improved permeability.
[0182] Table 8: Summary of Sequence Listing
[0183]
[0184]
[0185] Equivalence
[0186] The above-described embodiments are proposed to illustrate the present invention and should not be construed as imposing any limitation on the scope of the present invention. Obviously, without departing from the basic principles of the present invention, many modifications and changes can be made to the specific embodiments of the present invention described above and in the embodiments. All such modifications and changes are intended to be covered by the application. Sequence Listing <110> A*STAR <120> Peptides and compounds that bind to elongation initiation factor 4E <130> 9869sg5793 <160> 47 <170> PatentIn version 3.5 <210> 1 <211> 9 <212> PRT <213> Artificial sequence <220> <223> SEQ ID NO: 1 <220> <221> MISC_FEATURE <222> (3) <223> Xaa can be threonine, methionine or leucine <220> <221> MISC_FEATURE <222> (5)..(6) <223> Xaa can be a hydrophobic amino acid, an aromatic amino acid, a modified hydrophobic amino acid, or a modified aromatic amino acid. <220> <221> MISC_FEATURE <222> (7)..(8) <223> Xaa can be any naturally occurring amino acid, non-naturally occurring amino acid, or synthetic amino acid. <400> 1 Cys Glu Xaa Gly Xaa Xaa Xaa Xaa Cys 1 5 <210> 2 <211> 11 <212> PRT <213> Artificial sequence <220> <223> SEQ ID NO: 2 <400> 2 Ala Cys Glu Met Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> 3 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 3 Cys Glu Met Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> 4 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 4 Ala Cys Glu Met Gly Phe Phe Ala Asp Cys Gly 1 5 10 <210> 5 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 5 Ala Cys Glu Met Gly Phe Phe Lys Asp Cys Gly 1 5 10 <210> 6 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 6 Ala Cys Glu Met Gly Phe Phe Leu Asp Cys Gly 1 5 10 <210> 7 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 7 Cys Glu Met Gly Phe Phe Ala Asp Cys 1 5 <210> 8 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 8 Lys Lys Arg Tyr Ser Arg Asp Phe Leu Leu Ala Leu Gln Lys 1 5 10 <210> 9 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <220> <221> MISC_FEATURE <222> (3)..(9) <223> Xaa can be any naturally occurring amino acid, non-naturally occurring amino acid, or synthetic amino acid. <400> 9 Ala Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Gly Gly Gly Ser 1 5 10 <210> 10 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 10 Lys Lys Arg Tyr Ser Arg Asp Gln Leu Val Ala Leu 1 5 10 <210> 11 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <220> <221> MISC_FEATURE <222> (3) <223> Xaa can be threonine, methionine or leucine <220> <221> MISC_FEATURE <222> (7)..(8) <223> Xaa can be any naturally occurring amino acid, non-naturally occurring amino acid, or synthetic amino acid. <400> 11 Cys Glu Xaa Gly Phe Phe Xaa Xaa Cys 1 5 <210> 12 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <220> <221> MISC_FEATURE <222> (2) <223> Xaa can be any naturally occurring amino acid, non-naturally occurring amino acid, or synthetic amino acid. <220> <221> MISC_FEATURE <222> (4)..(5) <223> Xaa can be any naturally occurring amino acid, non-naturally occurring amino acid, or synthetic amino acid. <220> <221> MISC_FEATURE <222> (7) <223> Xaa can be any hydrophobic amino acid <400> 12 Tyr Xaa Arg Xaa Xaa Leu Xaa 1 5 <210> 13 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <220> <221> misc_feature <222> (3) <223> Xaa can be any naturally occurring amino acid <220> <221> misc_feature <222> (5)..(8) <223> Xaa can be any naturally occurring amino acid <400> 13 Cys Glu Xaa Gly Xaa Xaa Xaa Xaa Cys 1 5 <210> 14 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 14 Ala Cys Ala Met Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> 15 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 15 Ala Cys Glu Ala Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> 16 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 16 Ala Cys Glu Met Ala Phe Phe Gln Asp Cys Gly 1 5 10 <210> 17 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 17 Ala Cys Glu Met Gly Ala Phe Gln Asp Cys Gly 1 5 10 <210> 18 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 18 Ala Cys Glu Met Gly Phe Ala Gln Asp Cys Gly 1 5 10 <210> 19 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 19 Ala Cys Glu Met Gly Phe Phe Gln Ala Cys Gly 1 5 10 <210> 20 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 20 Ala Cys Asp Met Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> twenty one <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> twenty one Ala Cys Glu Ile Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> twenty two <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> twenty two Ala Cys Glu Leu Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> twenty three <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <220> <221> MOD_RES <222> (4) <223> Nle <400> twenty three Ala Cys Glu Leu Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> twenty four <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <220> <221> MISC_FEATURE <222> (4) <223> Cyclobutylalanine <400> twenty four Ala Cys Glu Ala Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> 25 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <220> <221> MOD_RES <222> (5) <223> bA <400> 25 Ala Cys Glu Met Ala Phe Phe Gln Asp Cys Gly 1 5 10 <210> 26 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <220> <221> MOD_RES <222> (5) <223> Glycine methylation to sarcosine <400> 26 Ala Cys Glu Met Gly Phe Phe Gln Asp Cys Gly 1 5 10 <210> 27 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 27 Ala Cys Glu Met Pro Phe Phe Gln Asp Cys Gly 1 5 10 <210> 28 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 28 Ala Cys Glu Met Gly Tyr Phe Gln Asp Cys Gly 1 5 10 <210> 29 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 29 Ala Cys Glu Met Gly Trp Phe Gln Asp Cys Gly 1 5 10 <210> 30 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 30 Ala Cys Glu Met Gly Leu Phe Gln Asp Cys Gly 1 5 10 <210> 31 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 31 Ala Cys Glu Met Gly Phe Leu Gln Asp Cys Gly 1 5 10 <210> 32 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 32 Ala Cys Glu Met Gly Phe Tyr Gln Asp Cys Gly 1 5 10 <210> 33 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 33 Ala Cys Glu Met Gly Phe Trp Gln Asp Cys Gly 1 5 10 <210> 34 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 34 Ala Cys Glu Met Gly Tyr Tyr Gln Asp Cys Gly 1 5 10 <210> 35 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 35 Ala Cys Glu Met Gly Leu Leu Gln Asp Cys Gly 1 5 10 <210> 36 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 36 Ala Cys Glu Met Gly Phe Phe Gly Asp Cys Gly 1 5 10 <210> 37 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 37 Leu Pro Glu Thr Gly Gly 1 5 <210> 38 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 38 Cys Glu Met Gly Phe Phe Gln Asp Cys 1 5 <210> 39 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 39 Ala Cys Glu Thr Gly Phe Phe Thr Gly Cys Gly 1 5 10 <210> 40 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 40 Ala Cys Glu Leu Gly Tyr Tyr Asn Asp Cys Gly 1 5 10 <210> 41 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 41 Ala Cys Glu Thr Gly Phe Phe Leu Lys Cys Gly 1 5 10 <210> 42 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 42 Ala Cys Glu Leu Gly Phe Tyr Arg Leu Cys Gly 1 5 10 <210> 43 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 43 Ala Cys Glu Thr Gly Phe Phe Leu Arg Cys Gly 1 5 10 <210> 44 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 44 Ala Cys Glu Thr Gly Tyr Phe Ser Gln Cys Gly 1 5 10 <210> 45 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 45 Ala Cys Ile His Ser Pro Thr Ser Leu Cys Gly 1 5 10 <210> 46 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 46 Ala Cys Glu Thr Gly Phe Tyr Lys Thr Cys Gly 1 5 10 <210> 47 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence <400> 47 Ala Cys Glu Met Gly Tyr Phe Gly Asn Cys Gly 1 5 10
Claims
1. A peptide, wherein the amino acid sequence of the peptide is selected from the group consisting of: ACEMGFFQDCG (SEQ ID NO: 2), CEMGFFQDCG (SEQ ID NO: 3), ACEMGFFADCG (SEQ ID NO: 4), ACEMGFFKDCG (SEQ ID NO: 5), ACEMGFFLDCG (SEQ ID NO: 6), CEMGFFADC (SEQ ID NO: 7), ACEMGFFQACG (SEQ ID NO: 19), ACELGFFQDCG (SEQ ID NO: 22), ACEMGYFQDCG (SEQ ID NO: 28), ACEMGFYQDCG (SEQ ID NO: 32), ACEMGYYQDCG (SEQ ID NO: 34), ACEMGFFGDCG (SEQ ID NO: 36) and CEMGFFQDC (SEQ ID NO: 38), Two of the cysteine residues are linked by a disulfide bond.
2. The peptide of claim 1, wherein the amino acid sequence of the peptide is selected from the group consisting of ACEMGFFQDCG (SEQ ID NO: 2), CEMGFFQDCG (SEQ ID NO: 3), ACEMGFFADCG (SEQ ID NO: 4), ACEMGFFKDCG (SEQ ID NO: 5), ACEMGFFLDCG (SEQ ID NO: 6), CEMGFFADC (SEQ ID NO: 7), ACEMGYFQDCG (SEQ ID NO: 28) and ACEMGFYQDCG (SEQ ID NO: 32).
3. The peptide according to claim 1, wherein the peptide consists of the amino acid sequence CEMGFFADC (SEQ ID NO: 7).
4. A pharmaceutical composition comprising the peptide according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.
